Drug intelligence / Profile preview

3D062

Development stage: Preclinical
Lead developer: 3D Medicines
Modality: Small Molecules
Administration: Subcutaneous

Overview

3D062 is a preclinical-stage small molecule KRAS inhibitor being developed by 3D Medicines. The compound is designed to target and block oncogenic KRAS signaling, which is a critical driver in the development and progression of various solid tumors. While the specific KRAS mutation(s) targeted (such as G12C or G12D) and the precise binding mechanism have not been publicly disclosed, the drug is intended for the treatment of multiple oncology indications. It is currently part of 3D Medicines' pipeline of targeted oncology assets alongside other immunotherapies and radionuclide conjugates.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on 3D062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D062.

Explore the full profile